I-MAB (IMAB) Price-to-Tangible-Book : 0.48 (As of May. 01, 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Price-to-Tangible-Book?

As of today (2024-05-01), I-MAB's share price is $1.76. I-MAB's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was $3.66. Hence, I-MAB's Price to Tangible Book Ratio of today is 0.48.

The historical rank and industry rank for I-MAB's Price-to-Tangible-Book or its related term are showing as below:

IMAB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.63 Med: 4.14 Max: 8.8
Current: 0.63

During the past 7 years, I-MAB's highest Price to Tangible Book Ratio was 8.80. The lowest was 0.63. And the median was 4.14.

IMAB's Price-to-Tangible-Book is ranked better than
90.5% of 1221 companies
in the Biotechnology industry
Industry Median: 2.69 vs IMAB: 0.63

A closely related ratio is called PB Ratio. As of today, I-MAB's share price is $1.76. I-MAB's Book Value per Sharefor the quarter that ended in Jun. 2023 was $4.14. Hence, I-MAB's P/B Ratio of today is 0.43.

I-MAB Price-to-Tangible-Book Historical Data

The historical data trend for I-MAB's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Price-to-Tangible-Book Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

4.14

5.64

0.92

0.68

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial								5.64	1.68	0.92	0.82	0.68

Competitive Comparison of I-MAB's Price-to-Tangible-Book

For the Biotechnology subindustry, I-MAB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where I-MAB's Price-to-Tangible-Book falls into.

I-MAB Price-to-Tangible-Book Calculation

I-MAB's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	1.76	/	3.66
	=	0.48

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

I-MAB Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of I-MAB's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.